Discover how lenacapavir, a revolutionary HIV prevention tool, will be available for just $40 annually to 120 low- and middle ...

Lenacapavir is a long-acting injectable antiretroviral drug developed by Gilead Sciences. It is administered just twice a year and has demonstrated over 99.9% effectiveness in preventing HIV ...

Australia is facing a mounting sexual health crisis, with case numbers now double what they were just a decade ago.

A groundbreaking injectable drug, lenacapavir, offers renewed hope in the fight against HIV. Set to be available in 2027 in ...

An HIV prevention drug will be made available at a new, low cost in 120 low- and middle-income countries starting in 2027, according to an announcement yesterday. The move is being called a “once-in-a ...

Linda-Gail Bekker, who helped prove the drug Lenacapavir’s effectiveness, tells The Independent that $40 doses bring hope – ...

Global health agencies announced Wednesday that generic versions of a groundbreaking injectable drug to prevent HIV will be ...

This antiretroviral has shown unprecedented results in HIV prevention, requiring only two injections per year. Its ...

Lenacapavir, approved by the FDA in June, requires only two shots a year. US insurers don't cover it, but access will soon ...

The HIV/AIDS prevalence rate in Angola has decreased from 2 percent to 1.6 percent over the last 20 years, the Secretary of State for Public Health, Carlos Alberto Pinto de Sousa, revealed in Luanda.

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Generic versions of a breakthrough injectable HIV-prevention drug will be made available for just $40 annually across 120 low ...